Clinical differentiation Position Droplette’s patented Microinfusion technology as a clinically backed differentiator that enables large molecules and growth factor capsules to reach the dermis without needles, appealing to dermatology-focused practices and medical spa partners seeking evidence-based skincare delivery.

Growth factor expansion capitalize on recent launches of Growth Factor capsules and pharma-grade variants to target high-end clinics, pharma partners, and cold-chain capable distributors looking for premium, science-backed delivery systems and differentiated product lines.

Award & credibility Leverage TIME Best Inventions recognition and Edison Award for Best New Product to build outreach to venture-backed skincare brands, hospitals, and clinics seeking validated, award-winning technologies to bolster patient trust and case acceptance.

Funding signals With ongoing funding of around 21 million and revenue in the mid single digits to low tens of millions, pursue partnerships with mid-market distributors and specialty retailers that value growth-stage brands with scalable manufacturing and compelling clinical narratives.

Multi-disciplinary appeal Highlight the cross-functional team of engineers, biologists, dermatologists, and skincare veterans to attract collaborations with R&D departments at larger cosmetic manufacturers, contract manufacturers, and research institutions seeking innovative delivery platforms.